BR112019003419A2 - composição de vacina multivalente - Google Patents
composição de vacina multivalenteInfo
- Publication number
- BR112019003419A2 BR112019003419A2 BR112019003419-6A BR112019003419A BR112019003419A2 BR 112019003419 A2 BR112019003419 A2 BR 112019003419A2 BR 112019003419 A BR112019003419 A BR 112019003419A BR 112019003419 A2 BR112019003419 A2 BR 112019003419A2
- Authority
- BR
- Brazil
- Prior art keywords
- antigens
- ipv
- rotavirus
- antigen
- aluminum hydroxide
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 229940031348 multivalent vaccine Drugs 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 7
- 102000036639 antigens Human genes 0.000 abstract 7
- 108091007433 antigens Proteins 0.000 abstract 7
- 241000702670 Rotavirus Species 0.000 abstract 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 abstract 3
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 abstract 2
- 230000002163 immunogen Effects 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- 241000588832 Bordetella pertussis Species 0.000 abstract 1
- 102000014914 Carrier Proteins Human genes 0.000 abstract 1
- 108010078791 Carrier Proteins Proteins 0.000 abstract 1
- 241000193449 Clostridium tetani Species 0.000 abstract 1
- 241000186216 Corynebacterium Species 0.000 abstract 1
- 241000606768 Haemophilus influenzae Species 0.000 abstract 1
- 241000700721 Hepatitis B virus Species 0.000 abstract 1
- 201000005702 Pertussis Diseases 0.000 abstract 1
- 208000000474 Poliomyelitis Diseases 0.000 abstract 1
- 241000422848 Taxodium mucronatum Species 0.000 abstract 1
- 229940001442 combination vaccine Drugs 0.000 abstract 1
- 229960003983 diphtheria toxoid Drugs 0.000 abstract 1
- 229940047650 haemophilus influenzae Drugs 0.000 abstract 1
- 230000005847 immunogenicity Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000004321 preservation Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000001179 sorption measurement Methods 0.000 abstract 1
- 229960000814 tetanus toxoid Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/15—Reoviridae, e.g. calf diarrhea virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/099—Bordetella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A61K39/13—Poliovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12311—Rotavirus, e.g. rotavirus A
- C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
a presente invenção refere-se a vacina (s) combinada (s) imunogênica estável(is), compreendendo uma mistura de antígenos para prevenção e profilaxia de infecções causadas por vírus rotavírus, poliomielite, haemophilus influenzae, corynebacterium diphteriae, clostridium tetani, bordetella pertussis e vírus da hepatite b. a presente invenção proporciona particularmente uma vacina de combinação multivalente compreendendo: i) antígenos de salk ipv ou sabino ipv (ipv) significativamente reduzidos em dose, ii) antígeno (s) de rotavírus inativados de calor injetáveis obtidos a partir de cepas de rotavírus (cdc-9), iii) conjugado de proteína veículo hib prp, iv) antígeno de coqueluche de célula completa com imunogenicidade e estabilidade melhoradas, v) frações homogêneas de toxóide de difteria e toxóide do tétano. o processo de produzir tais composições de vacinais estáveis e imunogênicas i) por adsorção individual da dose reduziu a ipv. os antígenos de irv em hidróxido de alumínio e conservação de outros antígenos não adsorvidos ou adsorvidos em fosfato de alumínio, hidróxido de alumínio, em uma combinação de hidróxido de alumínio e fosfato de alumínio e ii) usando uma ordem particular de adição de antígenos durante a mistura.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201621029037 | 2016-08-26 | ||
| IN201621029037 | 2016-08-26 | ||
| PCT/IB2017/055100 WO2018037365A1 (en) | 2016-08-26 | 2017-08-24 | Multivalent vaccine composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019003419A2 true BR112019003419A2 (pt) | 2019-05-21 |
Family
ID=60083359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019003419-6A BR112019003419A2 (pt) | 2016-08-26 | 2017-08-24 | composição de vacina multivalente |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US11235054B2 (pt) |
| EP (1) | EP3503917A1 (pt) |
| JP (3) | JP7384667B2 (pt) |
| KR (1) | KR102607295B1 (pt) |
| CN (1) | CN110691611A (pt) |
| AU (1) | AU2017316768B2 (pt) |
| BR (1) | BR112019003419A2 (pt) |
| CA (1) | CA3032901A1 (pt) |
| CU (1) | CU24682B1 (pt) |
| EA (1) | EA201900117A1 (pt) |
| IL (1) | IL264605B2 (pt) |
| MX (1) | MX2019001780A (pt) |
| MY (1) | MY191163A (pt) |
| PE (1) | PE20200004A1 (pt) |
| PH (1) | PH12019500404A1 (pt) |
| SG (1) | SG11201900365WA (pt) |
| WO (1) | WO2018037365A1 (pt) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017316768B2 (en) * | 2016-08-26 | 2024-04-11 | Serum Institute Of India Private Limited | Multivalent vaccine composition |
| US11793873B2 (en) | 2017-05-10 | 2023-10-24 | University Of Massachusetts | Bivalent dengue/hepatitis B vaccines |
| JOP20190242A1 (ar) * | 2018-10-12 | 2020-04-12 | Serum Institute Of India Pvt Ltd | تركيبة لقاح توليفي تشمل فيروس شلل الأطفال ذو جرعة مخفّضة خاملة التنشيط وطريقة لتحضيرها |
| JOP20200214A1 (ar) | 2019-09-03 | 2021-03-03 | Serum Institute Of India Pvt Ltd | تركيبات مولدة للمناعة ضد الأمراض المعوية وطرق لتحضيرها |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2329843A3 (en) * | 2005-04-18 | 2011-09-14 | Novartis Vaccines and Diagnostics, Inc. | Expressing Hepatitis B Virus surface antigen for vaccine preparation |
| PT2066344E (pt) * | 2006-09-07 | 2011-07-05 | Glaxosmithkline Biolog Sa | Vacina de combinação de poliovírus inactivado |
| PE20100365A1 (es) * | 2008-10-24 | 2010-05-21 | Panacea Biotec Ltd | Novedosas vacunas de combinacion con tos ferina de celulas enteras y metodo para su elaboracion |
| CN102695522B (zh) * | 2009-05-12 | 2016-10-19 | 美国政府(由卫生和人类服务部、疾病控制和预防中心的部长所代表) | 新的人轮状病毒株和疫苗 |
| CN103442730B (zh) * | 2011-01-05 | 2016-08-17 | 巴拉特生物技术国际有限公司 | 组合七价疫苗 |
| CA2828844C (en) * | 2011-03-02 | 2020-07-14 | Novartis Ag | Combination vaccines with lower doses of antigen and/or adjuvant |
| CU24510B1 (es) * | 2014-10-07 | 2021-05-12 | Serum Institute Of India Pvt Ltd | Método para la composición de una vacuna contra la poliomielitis, con poliovirus inactivados y adsorción en coadyuvantes |
| AU2017316768B2 (en) * | 2016-08-26 | 2024-04-11 | Serum Institute Of India Private Limited | Multivalent vaccine composition |
-
2017
- 2017-08-24 AU AU2017316768A patent/AU2017316768B2/en active Active
- 2017-08-24 PE PE2019000409A patent/PE20200004A1/es unknown
- 2017-08-24 MX MX2019001780A patent/MX2019001780A/es unknown
- 2017-08-24 CU CU2019000013A patent/CU24682B1/es unknown
- 2017-08-24 CN CN201780052380.5A patent/CN110691611A/zh active Pending
- 2017-08-24 MY MYPI2019001011A patent/MY191163A/en unknown
- 2017-08-24 JP JP2019532214A patent/JP7384667B2/ja active Active
- 2017-08-24 IL IL264605A patent/IL264605B2/en unknown
- 2017-08-24 WO PCT/IB2017/055100 patent/WO2018037365A1/en active Search and Examination
- 2017-08-24 SG SG11201900365WA patent/SG11201900365WA/en unknown
- 2017-08-24 KR KR1020197008377A patent/KR102607295B1/ko active IP Right Grant
- 2017-08-24 EP EP17783992.5A patent/EP3503917A1/en active Pending
- 2017-08-24 US US16/327,513 patent/US11235054B2/en active Active
- 2017-08-24 EA EA201900117A patent/EA201900117A1/ru unknown
- 2017-08-24 BR BR112019003419-6A patent/BR112019003419A2/pt active Search and Examination
- 2017-08-24 CA CA3032901A patent/CA3032901A1/en active Pending
-
2019
- 2019-02-26 PH PH12019500404A patent/PH12019500404A1/en unknown
-
2021
- 2021-07-16 JP JP2021118038A patent/JP2021181445A/ja active Pending
-
2023
- 2023-10-06 JP JP2023174503A patent/JP2024009899A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024009899A (ja) | 2024-01-23 |
| JP2019526635A (ja) | 2019-09-19 |
| AU2017316768B2 (en) | 2024-04-11 |
| EP3503917A1 (en) | 2019-07-03 |
| PH12019500404A1 (en) | 2020-01-20 |
| IL264605B2 (en) | 2023-04-01 |
| IL264605B (en) | 2022-12-01 |
| KR102607295B1 (ko) | 2023-11-29 |
| MY191163A (en) | 2022-06-03 |
| WO2018037365A1 (en) | 2018-03-01 |
| CU24682B1 (es) | 2023-10-06 |
| PE20200004A1 (es) | 2020-01-06 |
| CU20190013A7 (es) | 2019-10-04 |
| KR20190142311A (ko) | 2019-12-26 |
| AU2017316768A1 (en) | 2019-04-11 |
| JP7384667B2 (ja) | 2023-11-21 |
| US20190175722A1 (en) | 2019-06-13 |
| CN110691611A (zh) | 2020-01-14 |
| CA3032901A1 (en) | 2018-03-01 |
| SG11201900365WA (en) | 2019-02-27 |
| US11235054B2 (en) | 2022-02-01 |
| MX2019001780A (es) | 2020-01-13 |
| IL264605A (en) | 2019-02-28 |
| EA201900117A1 (ru) | 2019-09-30 |
| JP2021181445A (ja) | 2021-11-25 |
| WO2018037365A8 (en) | 2018-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019003419A2 (pt) | composição de vacina multivalente | |
| GEP20227386B (en) | Immunogenic composition having improved stability, enhanced immunogenicity and reduced reactogenicity and process for preparation thereof | |
| BR112013017171A2 (pt) | vacina de combinação imunogênica estável, processo de preparação de vacina de combinação estável, método de uso de moléculas antigênicas e método de administração a indivíduos humanos | |
| AR092896A1 (es) | Composiciones inmunogenicas | |
| PE20100366A1 (es) | Novedosas composiciones de vacuna con tos ferina acelular asi como el metodo para su elaboracion | |
| PE20220774A1 (es) | Conjugados proteina-polisacarido de estreptococo grupo b, metodos para producir conjugados, composiciones inmunogenas que comprenden conjugados y sus usos | |
| BR112018007525A2 (pt) | composições imunogênicas de circovírus suíno tipo 3 e métodos de produzir e usar as mesmas | |
| AR088907A1 (es) | Vacuna | |
| CO6430435A2 (es) | Nuevas vacunas combinadas con células completas de pertussis y método de fabricación de las mismas | |
| EA201700177A1 (ru) | Улучшенный способ конъюгирования и полученные с помощью него новые синтетические конъюгаты олигосахарида с белком | |
| MX2018015506A (es) | Vacuna contra virus de bronquitis infecciosa. | |
| RU2016110576A (ru) | Бактериальная вакцина и способы ее получения | |
| PE20211648A1 (es) | Composicion de vacuna combinada que comprende dosis reducidas del virus inactivado de la polio y metodo de preparacion de la misma | |
| NZ585367A (en) | Methods for designing and preparing vaccines comprising directed sequence polymer compositions via the directed expansion of epitopes | |
| RU2015111987A (ru) | Несшитые бесклеточные коклюшные антигены для применения в комбинированных вакцинах | |
| AR101256A1 (es) | Composición vacunal que comprende ipv y ciclodextrinas | |
| AR117191A1 (es) | Composiciones inmunogénicas | |
| RU2014147491A (ru) | Антигены и антигенные композиции | |
| EA202191145A1 (ru) | Вакцина виб 4/91 с гетерологичным шиповидным белком | |
| AR118407A1 (es) | Composición de vacuna multivalente | |
| EA202191147A1 (ru) | Вакцина виб h52 с гетерологичным шиповидным белком | |
| AR120233A1 (es) | Proceso de producción, recuperación y purificación de polisacárido capsular polirribosil ribitol fosfato (prp) y uso del mismo | |
| AR097217A1 (es) | Composiciones inmunógenas de combinación | |
| RU2015101149A (ru) | Комбинированная вакцина для профилактики коклюша, дифтерии, столбняка, гепатита в и инфекции, вызываемой haemophilus influenzae тип в |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |